What we do

ExQor's CNS platform is able to target specific regions in the brain with large molecule drugs that solve unmet medical needs.

ExQor’s multi-patented CNS drug platform non-invasively crosses an intact blood brain barrier.  The blood brain barrier protects the brain. But the same barrier also prevents almost all drug treatments from gaining access to the brain

The barrier thus severely limits the creation and delivery of drugs to treat CNS diseases and disorders. The use of large molecule biologics is essentially barred. 


ExQor's bio-nanotechnology platform non-invasively delivers large molecule biologics to the brain and in therapeutically effective amounts. Among them are antibodies, growth factors, and other types of large molecule agents.

Brain Imaging

By using its CNS platform ExQor is also developing non-radioactive imaging agents that enable conventional MRI to have similar molecular level resolution to PET and its radioligands. This novel use of conventional MRI would globally enable many more clinics and operating in diverse environments to have access to new and powerful imaging-diagnostic capabilities.

This CNS imaging platform will also be used to early detect and monitor disease progression and its treatment by ExQor's biologics.


ExQor's ability to deliver biologics to brain opens up new approaches to treating CNS disorders that so far have been intractable. Our current pipeline includes treatments for:


HIV-1 associated neurocognitive disorders (HAND)

METH addiction


Post-COVID-19 effects on CNS are increasingly being reported. Via its patented platform ExQor is planning to deliver biologics to brain that could prevent and treat these often life-devastating effects such as long-term cognitive deficits and CNS-induced hypoxia.




© 2021 ExQor Technologies, Inc . All rights reserved